NVDA−4.40%AAPL+1.23%GOOGL−3.15%MSFT−2.23%AMZN−4.57%TSM−4.52%SPCX−9.14%META−6.98%
StockVS

NASDAQ · Medical Devices · USD

Profound Medical Corp. (PROF) Stock Analysis

Profound Medical Corp. (PROF) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 22, 2026

PROF

$5.76

+$0.07 (+1.23%)

Oct 22, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PROF with… →

PROF Key Statistics

As of Oct 22, 2026
Trading
Open
$5.66
Previous Close
$5.69
Day's Range
5.55–5.98
52-Week Range
4.80–8.95
Volume
342.86K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.56
Valuation
Market Cap
$210.47M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
11.03
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.99
Financials (FY)
Revenue (FY)
$16.10M+50.73%
Net Income (FY)
−$42.57M
Profit marginThe share of revenue left as profit after all costs and taxes.
−171.56%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
36.54M
1-Year Return
+6.27%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
191.37K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 22, 2026, PROF closed at $5.76, +6.27% over 1 year.

Profound Medical Corp. (PROF) has a market capitalization of $210.47M.

In fiscal 2025, PROF reported revenue of $16.10M.

PROF Stock Return by Calendar Year

Profound Medical Corp. (PROF) return since Oct 2019: what $10,000 became

1 year
$10,000 $10,627
+6.27%
5 years
$10,000 $4,011
−59.89%
Since Oct 2019
$10,000 $5,934
−40.66%

If you had invested $10,000 in Profound Medical Corp. (PROF) at the close on October 29, 2019, the earliest close on record here, it would have been worth $5,934 at the close on October 22, 2026: −40.66% in total, −7.20% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−26.81%
2025+4.79%
2024−11.54%
2023−22.04%
2022−3.03%
2021−45.38%
2020+87.76%
2019 (partial year)+12.81%

As of October 22, 2026.

PROF Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$16.10M−$42.57M−264.4%
2024$10.68M−$27.82M−260.4%
2023$7.20M−$28.32M−393.4%
2022$6.68M−$28.67M−429.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$16.10M$11.39M−$41.25M−$42.57M−264.4%
2024$10.68M$7.04M−$33.06M−$27.82M−260.4%
2023$7.20M$4.31M−$28.65M−$28.32M−393.4%
2022$6.68M$3.02M−$29.60M−$28.67M−429.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PROF Valuation vs Medical Devices Median

Median of 145 stocks
MetricPROFMedical Devices medianvs median
P/S ratio11.032.534.4x the median
Profit margin−171.56%−14.78%156.8 pts below

Medians across 145 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 22, 2026.

Recent News

All 16 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Profound Medical Corp. (PROF) is capitalised at $210.47M on the latest close. It is classified in the Medical Devices industry, within the Healthcare sector. Headcount on file is 162.

The most recent close on file for PROF is $5.76, dated October 22, 2026. That is +$0.07 (+1.23%) against the previous close. The 52-week range on file runs from $4.80 to $8.95. The latest close sits 20% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $16.10M. That is +50.73% against the prior fiscal year, when revenue was $10.68M. The same year closed with a net loss of $42.57M. The reported profit margin is −171.56%. That is 156.8 percentage points below the Medical Devices median of −14.78%. Earnings per share on a trailing basis come to −0.99.

Across the 4 fiscal years on file, revenue moves from $6.68M in 2022 to $16.10M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 11.03. On price-to-sales that is 4.4 times the Medical Devices median of 2.53. 145 Medical Devices companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is +6.27%. Across 5 years the annualized return works out at −16.70%. Beta against the wider market is reported at 0.56. Daily returns over the trailing 7 years annualize to a volatility of 69.22%.

Growth & Income

No dividend is on file for PROF.

So far in 2026 the total return is −26.81%. Across the complete calendar years on file, 2020 returned +87.76% and 2021 returned −45.38%. Of the 6 complete calendar years on file, 2 finished higher.

Peer Comparison

Profound Medical Corp. (PROF) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Profound Medical Corp. PROF $210.47M —
Abbott Laboratories ABT $177.38B 38.1
Medtronic plc. MDT $123.55B 23.7
Stryker Corporation SYK $117.79B 31.8

The Medical Devices industry average P/E ratio is 28.0x. Profound Medical Corp. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 22, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$177.38B

 MDT

Medtronic plc.

$123.55B

 SYK

Stryker Corporation

$117.79B

 BSX

Boston Scientific Corporation

$64.33B

 EW

Edwards Lifesciences Corporation

$51.93B

 GEHC

GE HealthCare Technologies Inc.

$32.26B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.17T

 JNJ

Johnson & Johnson

$644.91B

 ABBV

AbbVie Inc.

$503.96B

 UNH

UnitedHealth Group Incorporated

$381.46B

 MRK

Merck & Co., Inc.

$363.27B
View all Healthcare stocks →

About Profound Medical Corp.

Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. It operates in Canada, Germany, the United States, China, and Finland. Profound Medical Corp. is headquartered in Mississauga, Canada.

Visit website →